266 related articles for article (PubMed ID: 9344580)
21. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines.
Buquet-Fagot C; Lallemand F; Montagne MN; Mester J
Anticancer Drugs; 1997 Jul; 8(6):623-31. PubMed ID: 9300578
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells.
Mihara M; Shintani S; Kiyota A; Matsumura T; Wong DT
Int J Oncol; 2002 Jul; 21(1):95-101. PubMed ID: 12063555
[TBL] [Abstract][Full Text] [Related]
23. Cyclin-dependent kinase inhibitor roscovitine induces cell cycle arrest and apoptosis in rabbit retinal pigment epithelial cells.
Wu PC; Tai MH; Hu DN; Lai CH; Chen YH; Wu YC; Tsai CL; Shin SJ; Kuo HK
J Ocul Pharmacol Ther; 2008 Feb; 24(1):25-33. PubMed ID: 18370874
[TBL] [Abstract][Full Text] [Related]
24. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines.
Edamatsu H; Gau CL; Nemoto T; Guo L; Tamanoi F
Oncogene; 2000 Jun; 19(27):3059-68. PubMed ID: 10871858
[TBL] [Abstract][Full Text] [Related]
25. Involvement of cyclin-dependent kinases in axotomy-induced retinal ganglion cell death.
Lefèvre K; Clarke PG; Danthe EE; Castagné V
J Comp Neurol; 2002 May; 447(1):72-81. PubMed ID: 11967896
[TBL] [Abstract][Full Text] [Related]
26. Is olomoucine, a weak CDK2 inhibitor, able to induce apoptosis in cancer cells?
Wandl S; Wesierska-Gadek J
Ann N Y Acad Sci; 2009 Aug; 1171():242-9. PubMed ID: 19723061
[TBL] [Abstract][Full Text] [Related]
27. CDK-inhibitor olomoucine inhibits cell death after exposure of cell lines to cytosine-arabinoside.
Papazisis KT; Geromichalos GD; Kouretas D; Dimitriadis KA; Kortsaris AH
Cancer Lett; 1999 Apr; 138(1-2):221-6. PubMed ID: 10378797
[TBL] [Abstract][Full Text] [Related]
28. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine.
Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M
Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988
[TBL] [Abstract][Full Text] [Related]
29. Formation of p27-CDK complexes during the human mitotic cell cycle.
Soos TJ; Kiyokawa H; Yan JS; Rubin MS; Giordano A; DeBlasio A; Bottega S; Wong B; Mendelsohn J; Koff A
Cell Growth Differ; 1996 Feb; 7(2):135-46. PubMed ID: 8822197
[TBL] [Abstract][Full Text] [Related]
30. Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.
Havlícek L; Hanus J; Veselý J; Leclerc S; Meijer L; Shaw G; Strnad M
J Med Chem; 1997 Feb; 40(4):408-12. PubMed ID: 9046330
[TBL] [Abstract][Full Text] [Related]
31. Differential effects of 6-DMAP, olomoucine and roscovitine on Xenopus oocytes and eggs.
Flament S; Bodart JF; Bertout M; Browaeys E; Rousseau A; Vilain JP
Zygote; 2000 Feb; 8(1):3-14. PubMed ID: 10840869
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
33. The cyclin-dependent kinase (cdk) inhibitors, olomoucine and roscovitine, alter the expression of a molluscan circadian pacemaker.
Krucher NA; Meijer L; Roberts MH
Cell Mol Neurobiol; 1997 Oct; 17(5):495-507. PubMed ID: 9353591
[TBL] [Abstract][Full Text] [Related]
34. Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs.
Ribas J; Boix J
Exp Cell Res; 2004 Apr; 295(1):9-24. PubMed ID: 15051486
[TBL] [Abstract][Full Text] [Related]
35. S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells.
Hu B; Mitra J; van den Heuvel S; Enders GH
Mol Cell Biol; 2001 Apr; 21(8):2755-66. PubMed ID: 11283255
[TBL] [Abstract][Full Text] [Related]
36. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases.
Medema RH; Klompmaker R; Smits VA; Rijksen G
Oncogene; 1998 Jan; 16(4):431-41. PubMed ID: 9484832
[TBL] [Abstract][Full Text] [Related]
37. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
Cai D; Byth KF; Shapiro GI
Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
[TBL] [Abstract][Full Text] [Related]
38. [Antiproliferative effect of bcl-2 gene does not concern the control of mitotic events].
Neliudova AM; Brichkina AI; Rukhlova MP; Aksenov ND; Pospelova TV
Tsitologiia; 2004; 46(3):257-67. PubMed ID: 15214171
[TBL] [Abstract][Full Text] [Related]
39. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line.
Lee HR; Chang TH; Tebalt MJ; Senderowicz AM; Szabo E
Int J Oncol; 1999 Jul; 15(1):161-6. PubMed ID: 10375610
[TBL] [Abstract][Full Text] [Related]
40. CDK inhibitors induce mitochondria-mediated apoptosis through the activation of polyamine catabolic pathway in LNCaP, DU145 and PC3 prostate cancer cells.
Arisan ED; Obakan P; Coker-Gurkan A; Calcabrini A; Agostinelli E; Unsal NP
Curr Pharm Des; 2014; 20(2):180-8. PubMed ID: 23701543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
